Details for Patent: 8,648,098
✉ Email this page to a colleague
Which drugs does patent 8,648,098 protect, and when does it expire?
Patent 8,648,098 protects ESBRIET and is included in two NDAs.
This patent has forty patent family members in thirty countries.
Summary for Patent: 8,648,098
| Title: | Pirfenidone therapy and inducers of cytochrome P450 |
| Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. |
| Inventor(s): | Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
| Assignee: | Intermune, Inc. (Brisbane, CA) |
| Application Number: | 13/326,971 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,648,098 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,648,098
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | |||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | ||||
| Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,648,098
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E523197 | ⤷ Try a Trial | |||
| Australia | 2010212488 | ⤷ Try a Trial | |||
| Brazil | 112012013155 | ⤷ Try a Trial | |||
| Canada | 2710014 | ⤷ Try a Trial | |||
| Chile | 2012000952 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
